Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 18/20 | 0.68 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29731573 | 0.87 | NPBWR1 (0.57) | NPBWR1MCHR1PKM | |
| SCHEMBL29731534 | 0.87 | NPBWR1 (0.57) | NPBWR1MCHR1HTTALDH1A1PKM | |
| SCHEMBL24640501 | 0.87 | NPBWR1 (0.57) | NPBWR1MCHR1PKM | |
| SCHEMBL27435433 | 0.84 | NPBWR1 (0.54) | NPBWR1MCHR1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL14844531 | 0.84 | NPBWR1 (0.84) | NPBWR1MCHR1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL2551062 | 0.82 | NPBWR1 (0.77) | NPBWR1MCHR1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL24687649 | 0.81 | NPBWR1 (0.75) | NPBWR1MCHR1HTTALDH1A1SMN1; SMN2 | |
| SCHEMBL29191961 | 0.81 | NPBWR1 (0.66) | NPBWR1MCHR1 | |
| SCHEMBL4681881 | 0.80 | NPBWR1 (0.57) | NPBWR1MCHR1PKM | |
| SCHEMBL24640482 | 0.79 | NPBWR1 (0.48) | NPBWR1MCHR1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| EP-4291560-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2023-12-20 | — | — | EP | disclosed |
| CN-116848114-A | Tricyclic derivatives useful as PARP7 inhibitors | 北京加科思新药研发有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022170974-A9 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022170974-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022156708-A1 | PARP7 ENZYME INHIBITOR | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336629-A1 | Tricyclic Derivatives Useful As PARP7 Inhibitors | PARP1, PARP2, PARP11 | NPBWR1 4282/4885MCHR1 4705/4885HTT 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.